Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo

L. Koranyi, F. Peterfy, J. Szabo, A. Török, M. Guóth, G. Tamás

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The effect of gut glucagon-like immunoreactivity (GLI) devoid of pancreatic glucagon was studied in piglets. All glucagon-like peptides with an accessible C-terminal were removed from the gut extract by specific antibodies reacting with the C-terminal of the glucagon molecule. Endogenous secretion of pancreatic and gut glucagon was blocked by somatostatin infusion, and then the purified gut glucagon preparation was infused. The latter prevented the hypoglycemia resulting from somatostatin infusion, and increased the glucagon level detectable by C-terminal specific antibodies in the blood of the animals. This rise was significant statistically from the 30th min of GLI administration (26.7 ± 7.2 pg/ml versus 137.0 ± 67.0 pg/ml; P <0.05) and increased until the end of the infusion (90th min, 218 ± 60 pg/ml; P <0.005). It has been suggested that, owing to the in vivo enzymatic degradation of the infused gut glucagon, biologically active ' pancreatic' glucagon fractions are formed extracellularly.

Original languageEnglish
Pages (from-to)792-794
Number of pages3
JournalDiabetes
Volume30
Issue number9
Publication statusPublished - 1981

Fingerprint

Glucagon-Like Peptides
Glucagon
Somatostatin
Antibodies
Hypoglycemia
glucagon-like-immunoreactivity

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Koranyi, L., Peterfy, F., Szabo, J., Török, A., Guóth, M., & Tamás, G. (1981). Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo. Diabetes, 30(9), 792-794.

Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo. / Koranyi, L.; Peterfy, F.; Szabo, J.; Török, A.; Guóth, M.; Tamás, G.

In: Diabetes, Vol. 30, No. 9, 1981, p. 792-794.

Research output: Contribution to journalArticle

Koranyi, L, Peterfy, F, Szabo, J, Török, A, Guóth, M & Tamás, G 1981, 'Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo', Diabetes, vol. 30, no. 9, pp. 792-794.
Koranyi, L. ; Peterfy, F. ; Szabo, J. ; Török, A. ; Guóth, M. ; Tamás, G. / Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo. In: Diabetes. 1981 ; Vol. 30, No. 9. pp. 792-794.
@article{502cddf565374c79b9831673ce83e345,
title = "Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo",
abstract = "The effect of gut glucagon-like immunoreactivity (GLI) devoid of pancreatic glucagon was studied in piglets. All glucagon-like peptides with an accessible C-terminal were removed from the gut extract by specific antibodies reacting with the C-terminal of the glucagon molecule. Endogenous secretion of pancreatic and gut glucagon was blocked by somatostatin infusion, and then the purified gut glucagon preparation was infused. The latter prevented the hypoglycemia resulting from somatostatin infusion, and increased the glucagon level detectable by C-terminal specific antibodies in the blood of the animals. This rise was significant statistically from the 30th min of GLI administration (26.7 ± 7.2 pg/ml versus 137.0 ± 67.0 pg/ml; P <0.05) and increased until the end of the infusion (90th min, 218 ± 60 pg/ml; P <0.005). It has been suggested that, owing to the in vivo enzymatic degradation of the infused gut glucagon, biologically active ' pancreatic' glucagon fractions are formed extracellularly.",
author = "L. Koranyi and F. Peterfy and J. Szabo and A. T{\"o}r{\"o}k and M. Gu{\'o}th and G. Tam{\'a}s",
year = "1981",
language = "English",
volume = "30",
pages = "792--794",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo

AU - Koranyi, L.

AU - Peterfy, F.

AU - Szabo, J.

AU - Török, A.

AU - Guóth, M.

AU - Tamás, G.

PY - 1981

Y1 - 1981

N2 - The effect of gut glucagon-like immunoreactivity (GLI) devoid of pancreatic glucagon was studied in piglets. All glucagon-like peptides with an accessible C-terminal were removed from the gut extract by specific antibodies reacting with the C-terminal of the glucagon molecule. Endogenous secretion of pancreatic and gut glucagon was blocked by somatostatin infusion, and then the purified gut glucagon preparation was infused. The latter prevented the hypoglycemia resulting from somatostatin infusion, and increased the glucagon level detectable by C-terminal specific antibodies in the blood of the animals. This rise was significant statistically from the 30th min of GLI administration (26.7 ± 7.2 pg/ml versus 137.0 ± 67.0 pg/ml; P <0.05) and increased until the end of the infusion (90th min, 218 ± 60 pg/ml; P <0.005). It has been suggested that, owing to the in vivo enzymatic degradation of the infused gut glucagon, biologically active ' pancreatic' glucagon fractions are formed extracellularly.

AB - The effect of gut glucagon-like immunoreactivity (GLI) devoid of pancreatic glucagon was studied in piglets. All glucagon-like peptides with an accessible C-terminal were removed from the gut extract by specific antibodies reacting with the C-terminal of the glucagon molecule. Endogenous secretion of pancreatic and gut glucagon was blocked by somatostatin infusion, and then the purified gut glucagon preparation was infused. The latter prevented the hypoglycemia resulting from somatostatin infusion, and increased the glucagon level detectable by C-terminal specific antibodies in the blood of the animals. This rise was significant statistically from the 30th min of GLI administration (26.7 ± 7.2 pg/ml versus 137.0 ± 67.0 pg/ml; P <0.05) and increased until the end of the infusion (90th min, 218 ± 60 pg/ml; P <0.005). It has been suggested that, owing to the in vivo enzymatic degradation of the infused gut glucagon, biologically active ' pancreatic' glucagon fractions are formed extracellularly.

UR - http://www.scopus.com/inward/record.url?scp=0019426675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019426675&partnerID=8YFLogxK

M3 - Article

C2 - 6114889

AN - SCOPUS:0019426675

VL - 30

SP - 792

EP - 794

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -